NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin 300134, China.
Department of Hepatobiliary Surgery, Tianjin First Center Hospital, Nankai District, Tianjin 300192, China.
Life Sci. 2020 Jul 1;252:117656. doi: 10.1016/j.lfs.2020.117656. Epub 2020 Apr 12.
Diabetes is considered as one of the important risks in the progression of Hepatocellular carcinoma(HCC). Ribosome binding protein 1 (RRBP1), a rough endoplasmic reticulum protein, plays an essential role in diabetes and various cancer. E2F transcription factor 1 (E2F1), an upstream transcription factor of RRBP1, shows promoting tumor progression effect in multifarious cancers. In this research, we tried to identify whether regulating E2F1/RRBP1 pathway could inhibit the proliferation and metastasis of HepG2 cells induced by high glucose.
Proteomic, bioinformatics, molecular biology including RT-qPCR and Western blot, cell biology containing Cell Counting Kit-8 (CCK-8), wound healing assay and transwell assay, and biochemistry analyses incorporating Luciferase assay and CHIP assay were used in this study.
High glucose promoted the proliferation and metastasis of HepG2 cells through up-regulating the expression of RRBP1. Bioinformatics analysis predicted that E2F1 might be the transcription factor of RRBP1. Knocking-down of E2F1 down-regulated mRNA and protein expression levels of RRBP1 in HepG2 cells significantly and suppressed the proliferation, migration and invasion of cells remarkably, Reverse effect was observed in cells that E2F1 was overexpressed. Meanwhile, luciferase and CHIP assay determined that E2F1 could bind to the RRBP1 promoter and promote the transcription of RRBP1. Finally, rescue assay verified the important role of RRBP1/E2F1 axis in the process of HepG2 cells proliferation and metastasis.
All of the above provided possibility to improve the efficiency of HCC complicated with diabetes treatment by regulating the E2F1/RRBP1 pathway.
糖尿病被认为是肝细胞癌(HCC)进展的重要危险因素之一。核糖体结合蛋白 1(RRBP1)是一种粗面内质网蛋白,在糖尿病和各种癌症中发挥重要作用。E2F 转录因子 1(E2F1)是 RRBP1 的上游转录因子,在多种癌症中表现出促进肿瘤进展的作用。在这项研究中,我们试图确定调节 E2F1/RRBP1 通路是否可以抑制高葡萄糖诱导的 HepG2 细胞的增殖和转移。
蛋白质组学、生物信息学、包括 RT-qPCR 和 Western blot 的分子生物学、包含细胞计数试剂盒-8(CCK-8)的细胞生物学、划痕愈合试验和 Transwell 试验以及包含荧光素酶测定和 CHIP 测定的生物化学分析用于本研究。
高葡萄糖通过上调 RRBP1 的表达促进 HepG2 细胞的增殖和转移。生物信息学分析预测 E2F1 可能是 RRBP1 的转录因子。E2F1 的敲低显着下调 HepG2 细胞中 RRBP1 的 mRNA 和蛋白表达水平,并显着抑制细胞的增殖、迁移和侵袭,而在过表达 E2F1 的细胞中观察到相反的效果。同时,荧光素酶和 CHIP 测定确定 E2F1 可以结合 RRBP1 启动子并促进 RRBP1 的转录。最后,挽救试验验证了 RRBP1/E2F1 轴在 HepG2 细胞增殖和转移过程中的重要作用。
所有这些都为通过调节 E2F1/RRBP1 通路提高合并糖尿病的 HCC 治疗效率提供了可能性。